The value of integrating national longitudinal shopping data into respiratory disease forecasting models.
AbbVie’s full year 2023 sees 6.4% net revenue drop
Share this article The immunology portfolio of AbbVie, which faced stiff competition from Humira biosimilars, saw revenues decrease by 9.6% to $26.14bn. Credit: Valery Zankovych